ITUS (ITUS) Reaches $4.45 After 8.00% Up Move; Euclidean Technologies Management Upped Entercom Communications (ETM) Position

January 16, 2018 - By Clifton Ray

Euclidean Technologies Management Llc increased Entercom Communications Corp (ETM) stake by 258.33% reported in 2017Q3 SEC filing. Euclidean Technologies Management Llc acquired 58,187 shares as Entercom Communications Corp (ETM)’s stock declined 37.42%. The Euclidean Technologies Management Llc holds 80,711 shares with $924,000 value, up from 22,524 last quarter. Entercom Communications Corp now has $1.61 billion valuation. The stock increased 0.88% or $0.1 during the last trading session, reaching $11.45. About 1.13 million shares traded. Entercom Communications Corp. (NYSE:ETM) has declined 15.65% since January 16, 2017 and is downtrending. It has underperformed by 32.35% the S&P500.

The stock of ITUS Corporation (NASDAQ:ITUS) is a huge mover today! The stock increased 9.87% or $0.3999 during the last trading session, reaching $4.4499. About 1.75M shares traded or 162.20% up from the average. ITUS Corporation (NASDAQ:ITUS) has declined 67.95% since January 16, 2017 and is downtrending. It has underperformed by 84.65% the S&P500.The move comes after 6 months positive chart setup for the $73.69 million company. It was reported on Jan, 16 by Barchart.com. We have $4.81 PT which if reached, will make NASDAQ:ITUS worth $5.89 million more.

Investors sentiment increased to 1.5 in Q3 2017. Its up 0.35, from 1.15 in 2017Q2. It is positive, as 15 investors sold ETM shares while 23 reduced holdings. 25 funds opened positions while 32 raised stakes. 25.83 million shares or 18.66% more from 21.77 million shares in 2017Q2 were reported. Barclays Public Ltd Company invested in 0% or 111,245 shares. Millennium Ltd Limited Liability Company has invested 0% in Entercom Communications Corp. (NYSE:ETM). Swiss Bank & Trust holds 38,400 shares or 0% of its portfolio. State Of New Jersey Common Pension Fund D has invested 0.01% of its portfolio in Entercom Communications Corp. (NYSE:ETM). Weber Alan W owns 475,406 shares or 2.56% of their US portfolio. Evercore Wealth Mngmt Limited Liability Com owns 6,000 shares. Blackrock Incorporated reported 0% stake. Kirr Marbach Limited Liability Com In has invested 0.09% of its portfolio in Entercom Communications Corp. (NYSE:ETM). Alpine Woods Investors Ltd Liability has invested 0.04% in Entercom Communications Corp. (NYSE:ETM). Huntington Bancorporation stated it has 1,131 shares or 0% of all its holdings. Aperio Grp Incorporated Ltd Company reported 14,488 shares stake. California State Teachers Retirement Sys invested in 44,708 shares. 151,586 were accumulated by Bankshares Of Montreal Can. Moreover, Bridgeway Capital Management Inc has 0.04% invested in Entercom Communications Corp. (NYSE:ETM). Morgan Stanley stated it has 0% of its portfolio in Entercom Communications Corp. (NYSE:ETM).

Among 3 analysts covering Entercom Communications (NYSE:ETM), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Entercom Communications had 5 analyst reports since August 18, 2015 according to SRatingsIntel. Noble Financial maintained the shares of ETM in report on Monday, July 31 with “Buy” rating. The rating was maintained by Noble Financial with “Buy” on Monday, July 24. Wells Fargo upgraded the shares of ETM in report on Tuesday, August 18 to “Outperform” rating. The firm earned “Equal-Weight” rating on Friday, December 11 by Stephens. The stock of Entercom Communications Corp. (NYSE:ETM) earned “Buy” rating by Noble Financial on Monday, November 27.

Euclidean Technologies Management Llc decreased Humana Inc (NYSE:HUM) stake by 2,100 shares to 7,860 valued at $1.92M in 2017Q3. It also reduced Kohls Corp (NYSE:KSS) stake by 15,200 shares and now owns 36,859 shares. Trinity Inds Inc (NYSE:TRN) was reduced too.

ITUS Corporation funds, develops, acquires, and licenses emerging technologies in the areas of biotechnology. The company has market cap of $73.69 million. The company, through its subsidiary, Anixa Diagnostics Corporation, is developing a platform called Cchek, a series of non-invasive, blood tests for the early detection of solid tumor based cancers. It currently has negative earnings. It has a collaborative research agreement with The Wistar Institute for the development and validation of Cchek.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.